CML: Live long and prosper

Blood

Volumn 118, Issue 17, 2011, Pages 4499-4500

  Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL DISCOMFORT; CANCER FATIGUE; CANCER PAIN; CHRONIC MYELOID LEUKEMIA; CLONE; CONSENSUS; DIARRHEA; DRUG TREATMENT FAILURE; EDEMA; HEADACHE; HUMAN; LEUKEMIA REMISSION; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; NAUSEA; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

EID: 80055066239     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-369017     Document Type: Note

References (6)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.NEngl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
2. Hughes TP, Hochhaus A, Branford S, Müller MC, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758-3765.
3. Mahon FX, Réa D, Guilhot J, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
4. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 20031;21(11):2138-2146.
5. Efficace R, Baccarani M, Breccia M, Alimena G, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554- 4560.
6. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733-3736.